Healio (5/29) reported that on May 28, the FDA “announced the approval of Tauvid [flortaucipir F18], an IV injection that is used to help image a specific characteristic of Alzheimer’s disease in the brain known as tau pathology.” The agency has approved Tauvid for “adults who have cognitive impairment and are being evaluated for Alzheimer’s disease, according to an FDA press release.” Tauvid “is a radioactive diagnostic agent that is indicated for positron emission tomography imaging of the brain” that is “used to assess the density and distribution of aggregated tau neurofibrillary tangles…which is a primary signal of Alzheimer’s disease, the release said.”(SOURCE: APA Headlines)
- ) strategy and implementation of activities aimed at increased supports for caregivers of persons with mental illness, in addition to the continued work of the Coalition and sustaining the collaboration between aging and behavioral health providers at the local level.
- Studies Support Effectiveness Of Ketamine, Esketamine For Difficult-To-Treat Depression, MDD With Suicidal Ideation, Expert Says
- In Small Study, Investigational Nondopamine Antipsychotic Show Signals It May Improve Psychosis Symptoms In Patients With Parkinson’s Disease
- Benzoate Treatment Appears To Improve Cognitive Function Among Women With Later-Stage Dementia In Small Study
- More Than One In Ten Patients Who Receive An ICD May Also Develop Anxiety Or Depression, Research Suggests